Biotech investing may not be the most obvious place for investors to look right now, but factors may be turning in the category's favor. Multiple rate cuts in the back half of 2025 and a friendlier regulatory regime may position biotech investing as a shrewd option to end the year. One biotech ETF, GDOC, may have a case to make as it sends a strong buy signal. See more: How Leading Emerging Market ETF GEM Assesses Investments The Future Health Care Equity ETF (GDOC) charges a 75 basis point fee for an acti ...